Recombinant human granulocyte colonystimulating factor (rHuG-CSF) may have a significant impact on preventing infections associated with chemotherapyinduced neutropenia, as well as shortening time to tree lineage engraftment following high-dose chemotherapy and progenitor transplantation. However, the scientific literature documenting evidence-based practice is insufficient and often misinterpreted. This review presents data and discusses the evidence for actual clinical practice in the use of rHuG-CSF in conventional cyclic chemotherapy, either prophylactic or therapeutic, and high-dose therapy, either in priming for mobilization or post-transplantation. In the past decade, many reports have based their conclusions on surrogate markers, and it is time to move towards evaluation of clinically relevant factors. Data must be generated prospectively based on current clinical practice, and several issues must be considered and evaluated to define the true clinical benefit of rHuG-CSF with or without stem-cell support. Evaluation should include complications and needs for resources as well as impact on toxicity and efficacy of conventional or high-dose chemotherapy.
Introduction
The exciting history of granulocyte colonystimulating factor (G-CSF) started in the early 1980s, when two groups of scientists working in the USA and Japan purified human G-CSF from different sources and characterized a haematopoietic colonystimulating factor, cloned complementary DNAs and, subsequently, expressed the G-CSF gene in bacterial and mammalian cells. A recombinant human (rHu) molecule was then synthesized bacterially by these pioneering scientists. The molecule had HE Johnsen rHuG-CSF in clinical haemato-oncology lineage-specific growth factor function by binding to receptors found on myeloid lineage-specific progenitors and end-stage neutrophils. Two forms have now been approved in clinical practice: r-metHuG-CSF (filgrastim) and rHuG-CSF (lenograstim) synthesized in Escherichia coli and Chinese hamster ovary cells, respectively. The structure of each form is different, and the latter is glycosylated. 1 In clinical practice, G-CSF has proven to be effective, first in the prophylaxis of chemotherapy-induced neutropenia, and secondly as a mobilizer of haematopoietic progenitor cells to the blood. These phenomena are a direct and/or indirect consequence of the biological function of the lineage-specific growth factor receptor interaction with its ligand molecule G-CSF. The expansion of myelopoiesis seems to be regulated by endogenous G-CSF production, acting in a complex network with other known or unknown endogenous regulators of haemopoiesis. The exact mechanism of the homeostasis within the haematopoietic system is unknown, which is reflected by the unexpected consequences of G-CSF administration as described below.
Initially, measuring efficacy involved the assessment of blood counts and fever in various clinical situations without hard clinical data on documented microbiological infections, antibiotic administration, cost of hospitalization or remission and survival rates. 2 Such endpoints should now be taken into consideration when randomized trials are used as evidence for actual clinical effect. Hopefully, these data will be available from future trials, including studies of new forms of long-acting rHuG-CSF with sustained duration in vivo. 3 This paper reviews the actual practice of rHuG-CSF administration and evaluates whether administration is based on proven evidence of cost-effectiveness gathered from randomized clinical trials.
Biology of G-CSF and its receptor
Marrow myelopoiesis is influenced by a hierarchy of regulatory growth factors, produced locally by the microenvironment and in distant tissues invaded by microorganisms. The immediate defence during bacterial infection depends on rapid and sufficient mobilization of neutrophils to blood and tissue. Maximal mobilization capacity demands a sufficient marrow pool and a large buffer capacity of neutrophils. This may vary depending on disease involvement or previous chemotherapy. The burst of neutrophils into the blood is believed to be mediated by cytokines like G-CSF causing an early, transient reduction in blood neutrophils within the first 30 min, followed by a rapid rise and neutrocytosis during the subsequent 24 h. Short-term (4 -6 days) administration of rHuG-CSF leads to increased bone marrow cellularity and increased myeloid : erythroid ratios. 4, 5 Marrow expansion, which can be visualized by magnetic resonance (MR) scanning, is paralleled by a release of stem and progenitor cells into the blood circulation. 6 It has been hypothesized that low numbers of circulating stem cells reflect the infrequent requirement for stem cell recruitment in steady-state haematopoiesis, which can be enhanced following marrow expansion. 7 Marrow stem cells are thought to express receptors for all the haematopoietic growth factors, hence different growth factors could mobilize stem cells to a greater or lesser extent. However, mobilization of G-CSF receptor-negative erythroid, megakaryocytic and lymphoid lineage progenitors strongly indicate that an HE Johnsen rHuG-CSF in clinical haemato-oncology indirect effect is responsible for the expansion of the haematopoietic system. 8, 9 Granulocyte colony-stimulating factor receptors are expressed on myeloid progenitor cells, mature neutrophils, platelets and monocytes. The receptor numbers increase with differentiation, and mature cells display the highest number per cell. The binding of G-CSF to its receptors reduces the number of available surface receptors as the receptor complex is internalized and degraded. The protein tyrosine kinases KAK1 and JAK2 are phosphorylated on tyrosine after the interaction of G-CSF with its receptor, and the Ras/MAP kinase pathway has been shown to be activated. The specific pathway activated to induce neutrophilic maturation and rapid release from the marrow pool to blood and tissue is unknown (reviewed in 10 ).
rHuG-CSF in cyclic chemotherapy
Clinically, the efficacy of G-CSF relates directly to its biological effect. It acts selectively on cells of the myeloid lineage, or indirectly on haematopoiesis by expanding all three lineages in general. Theoretically, both effects would be clinically useful in cyclic chemotherapy, although no evidence exists to support this.
In 1994 the American Society of Clinical Oncology (ASCO) recommended 'the use of hematopoietic colony-stimulating factors in some situations, e.g. to reduce the likelihood of febrile neutropenia when the expected incidence is ≥ 40%; after documented febrile neutropenia in a prior chemotherapy cycle to avoid infectious complications and maintain dose intensity in subsequent treatment cycles when chemotherapy dose reduction is not appropriate; and after high-dose chemotherapy with autologous progenitor cell transplantation. Colonystimulating factors are also effective in the mobilization of peripheral blood progenitor cells. Therapeutic initiation of CSFs in addition to antibiotics at the onset of febrile neutropenia should be reserved for patients at high risk for septic complications. 11 In a recent comparison of clinical practices between 1994 and 1997, 12 the actual clinical use of growth factors was more in accordance with ASCO recommendations, but this comparison outlined many remaining opportunities to reduce their use with no clinical harm. 'Many oncologists continue to support the use of CSF in scenarios and with scheduling criteria that the guidelines and evidence do not support. ASCO's evidence-based guidelines should be linked with formal continuous quality improvement initiatives to substantially improve the quality of supportive oncology care'. 12 -14 The following is a step-by-step presentation of randomized published studies ( Table 1 ). The first step concerns the use of rHuG-CSF in conventional cyclic therapy, either prophylactic or therapeutic.
PROPHYLACTIC ADMINISTRATION
Reductions in neutropenia, neutropenic fever and septicaemia have been documented in several large, randomized, controlled studies of non-Hodgkin's lymphoma, 15 acute myeloid/ lymphoid leukaemia, 16 -20 breast cancer, 21 and small-cell lung cancers (SCLC). 22 The data do not document a reduction in toxic deaths related to neutropenic infection, and these trials seem to have a substantially higher incidence of neutropenic fever compared with other trials of conventional chemotherapy. 23 It is acceptable that any licensing trial reporting a high incidence of neutropenic fever may be important in demonstrating the expected effects of rHuG-CSF in diminishing the risk of HE Johnsen rHuG-CSF in clinical haemato-oncology neutropenic fever. 22 It must be stressed, however, that intensive induction chemotherapy was used in this study, and this regime has not yet been documented effective in terms of event-free and overall survival.
The actual consequence of these results was that 5 -10% of patients treated with chemotherapy for SCLC, breast cancer or nonseminomatous germ cell tumours received prophylactic rHuG-CSF. Even more surprisingly, 50 -75% of patients received secondary prophylaxis following a previous documented febrile neutropenic episode. 12 The efficacy of such strategies has not been documented, but such practice may reflect an urgent need for prognostic factors or tests predicting the risk for febrile neutropenia or sepsis.
A striking observation in the above licensing studies was that the risk for febrile neutropenia was highest during the first cycle of chemotherapy. Prophylactic administration prevented the first episode, but did not reduce subsequent risk for neutropenic fever. These results may define a subgroup of patients with reduced haematopoietic reserves.
Blood neutrophil mobilization following one injection of rHuG-CSF may correlate with marrow cellularity, and the grade of mobilization may identify outpatients at risk for severe neutropenia and fever following cyclic chemotherapy. 24 Such a predictive test needs to be studied in future prospective trials as it may have important clinical implications. 25 First, during multiple cycles of chemotherapy such a test may select patients for dose intensification. Perhaps even more importantly, this test may select those requiring continuous rHuG-CSF prophylaxis to avoid prolonged neutropenia and severe infections during chemotherapy cycles. Moreover, unnecessary and expensive cytokine support during chemotherapy may be reduced in neutropenic patients with a normal absolute neutrophil count (ANC) response following a stimulation test. Secondly, the test may select patients who are candidates for other growth factor treatments. It must be confirmed whether the 24-h ANC release from the marginal pool correlates with, or is predictive of, insufficient haematopoiesis that can be corrected by subsequent CSF-induced expansion of marrow cellularity.
Reliable cost-benefit analysis of the pre-emptive use of rHuG-CSF is likely to progenitors with fast recovery potential 28 -30,48 Post-transplant rHuG-CSF Marginal effect on ANC recovery 50 -53,75 rHuG-CSF, recombinant human granulocyte colony-stimulating factor; ANC, absolute neutrophil count. 
HE

rHuG-CSF in high-dose therapy
The second step concerns the use of rHuG-CSF in high-dose therapy, either in priming for mobilization or post-transplant.
PRIMING FOR STEM AND PROGENITOR MOBILIZATION TO BLOOD
Dührsen et al. 27 were among the first to report the increases in various clonogenic haematopoietic progenitor cells on day 5 of rHuG-CSF administration in cancer patients. This observation was confirmed in several clinical studies documenting release of progenitor cells into the circulation, allowing harvest of peripheral blood progenitor cells (PBPCs) to be used in autoand allografting. 28 -36 There is substantial inter-patient variation in the peak levels of progenitor cells after rHuG-CSF administration, related to the extent of previous chemotherapy or radiation therapy in which agents have damaged marrow function and reduced stem and progenitor cell compartments. 37 -41 
TRANSPLANTATION OF PERIPHERAL BLOOD PROGENITOR GRAFTS
Sheridan et al. 42 examined the ability of rHuG-CSF-mobilized PBPCs to reconstitute haematopoiesis. Surprisingly, platelet recovery was significantly faster compared with transplantation with bone marrow, and this method has been applied widely in highdose therapy. Several uncontrolled trials document that G-CSF-primed autologous peripheral blood stem cell transplantation is advantageous over traditional unprimed bone marrow grafts in shortening time to engraftment and hospital stay. 35 Three randomized trials provide the necessary documentation for the beneficial shift from 'marrow to blood' grafts in actual clinical practice. 43 -45 In the enthusiasm, the intermediate step of comparing primed blood and primed marrow progenitors was overlooked.
Five-day treatment with rHuG-CSF HE Johnsen rHuG-CSF in clinical haemato-oncology increased marrow cellularity 10 -100-fold without any change in CD34+ cells, colonyforming cells, long-term culture-initiating cells and pre-colony-forming unit frequencies, corresponding to a 1-to 2-log increase in total number per volume of marrow aspirated. 46 This expansion was confirmed by MR imaging, 6 documenting a moderate increase in haematopoiesis on days 5 -7 that surprisingly continued to expand on days 12 -14 . Several clinical studies have documented that rHuG-CSFprimed marrow is a sufficient autograft, without any reported graft failures in over 100 patients. 47 -49 As a result of a recent randomized trial by Damiani et al. 48 in lymphoma patients, we may consider 'resetting the clock' and evaluating the outcome of high-dose therapy and engraftment of quality-assessed primed marrow grafts prospectively, taking into consideration the risk of severe infections and relapse. Such studies may validate the use of rHuG-CSF-primed marrow if quality is assessed in accordance with actual practice.
POST-TRANSPLANT PROPHYLAXIS
After it was established that PBPCs were capable of restoring haematopoiesis following high-dose therapy, several studies were performed to evaluate the benefits of rHuG-CSF treatment following transplantation. As expected, accelerated ANC recovery was identified, but the effect on clinically important endpoints was marginal. 50 -53 
Important issues in rHuG-CSF treatment
As mentioned above, r-metHuG-CSF and rHuG-CSF are structurally different due to glycosylation of the latter. In vitro studies indicate that glycosylation confers advantages in terms of stability to pH, temperature and proteases resulting in greater biological potency in vitro. 54 -56 An international standard assignment 57 documents a 28% increase in activity, which may not be reflected in vivo due to the complexity of regulation of haemopoiesis. One randomized study has documented greater potency compared with nonglycosylated rHuG-CSF in mobilization of PBPCs in healthy volunteers. 58 This observation was not confirmed in another randomized trial 59 and several nonrandomized trials 60 -63 involving patients primed for harvest of autografts. In an attempt to justify a randomized trial, a sequential study was performed, with the results documenting no significant differences in peak levels of mobilized CD34+ stem cells in blood ( Table 2 ). 62 The difference between normal donors and patients may reflect marginal differences in haematopoietic capacity. Although comparisons outside the setting of progenitor and stem cell mobilization are lacking (Table 3) , it is likely that glycosylation in such practice has no clinical relevance.
Future studies of rHuG-CSF priming should focus on more informative biological effects than numbers of CD34+ or colonyforming cells. 64 The stimulatory capacity of different doses and the timing of administration have not been, and may never be, fully established. 65 -70 This is because several investigators are now studying combination therapy, e.g. rHuG-CSF + recombinant human stem cell factor or rHuG-CSF + recombinant human thrombopoietin (given simultaneously or sequentially). 71 Furthermore, investigators are also exploring the role of other regulatory cytokines that protect normal cells from cytotoxic drugs. Finally, one potential drawback in the mobilization of normal progenitor cells that should not be HE Johnsen rHuG-CSF in clinical haemato-oncology 
TABLE 4: Proposed objectives for clinical validation of the use of haematopoietic growth factors
forgotten is the risk of tumour cell release into the circulation, which could induce metastatic disease. No physician wants patients to spend fewer days in hospital if that means a higher relapse rate. 72 Other essential issues must be considered and evaluated to define the true clinical effect of rHuG-CSF with or without transplantation.
Key questions are summarized in Table 3 . The most important may be to identify negative prognostic factors for endpoints, outlined in Table 4 . In daily practice such factors are widely known, although not formally identified, and are the background for the discussion of special circumstances in the ASCO recommendations: '…pre-existing neutropenia due to disease, extensive prior chemotherapy, previous irradiation to the pelvis or other areas containing large amounts of bone marrow; a history of recurrent febrile neutropenia while receiving earlier chemotherapy of similar or lesser dose intensity; or conditions potentially enhancing the risk of serious infection, e.g. decreased immune function, open wounds, or already active tissue infection… ' 11 The answers to several questions raised in small pilot studies of haematopoiesis during or following growth factor administration may be of more biological importance. The definition of a 'classical endocrinological stimulation test' should be clarified to identify patients with impaired marrow reserve. 24, 25, 73 Therapeutic measures to stimulate such a reduced capacity to sufficient function before chemotherapy are urgently needed. These measures should include studies of short-term growth factor administration in combination with earlyand late-acting factors, e.g. rHu-CSF, interleukin 3, Flt-3, G-CSF, granulocyte macrophage-CSF, macrophage-CSF, erythropoeitin, thrombopoietin and many others. If this is successful in clinical practice we may see more non-haematologic toxicity including mucositis following high-dose therapy. Recently, a potentially beneficial protective effect has been described in animals and humans after administration of keratinocyte growth factor. 74 In analogy to the protective effect of haematopoietic growth factors, other organ-specific factors may reduce toxicity and improve the quality of life for cancer patients undergoing therapy.
HE Johnsen rHuG-CSF in clinical haemato-oncology
Future needs
The classical approach in haemato-oncology in performing Phase I, II, III and IV trials must take into consideration complexities of design by the addition of supportive strategies, which may not act only as innocent bystanders. Too often in the past decade, trials with multiple variables (growth factors, allogeneic or autologous transplantation, purging, etc) have not resulted in scientific proof of which variable produced an observed clinical benefit. The shift from marrow to blood progenitor grafting in high-dose therapy for breast cancer is an example of a 'home-run' approach that does not benefit anyone, including patients.
Meaningful future trials will therefore become more difficult and expensive to conduct without international co-operation within the framework of good clinical practice. Such activity needs support from national and international government healthcare systems, insurance companies and patient groups to allow the most important nonprofit questions to be evaluated scientifically.
In the past decade, many reports have based their conclusions on surrogate markers, and it seems time to move towards evaluation of present practice, based on clinically relevant factors. Obviously such data must be generated prospectively. Several issues must be considered and evaluated to define the true clinical benefit of rHuG-CSF with or without stem cell support. These should include ( 
